BCCA Protocol Summary For Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with DOCEtaxel

**Protocol Code:**  
**Tumour Group:**  
**Contact Physician:**

**ELIGIBILITY:**
- Recurrent or metastatic squamous cell carcinoma of the head and neck including primary unknown
- ECOG performance status 0, 1 or 2

**TESTS:**
- Baseline: CBC & differential, platelets, liver enzymes
- Before each treatment: CBC & differential, platelets
- Before Cycle 4 and anytime if clinically indicated*: liver enzymes
  *See Precaution #5 for guidelines regarding hepatic dysfunction

**PREMEDICATIONS:**
- Dexamethasone 8 mg PO bid for 3 days starting one day prior to each administration of DOCEtaxel
- A minimum of 3 doses of dexamethasone pre-treatment are required
- Additional antiemetics are not usually required
- DOCEtaxel-induced onycholysis and cutaneous toxicity of the hands may be prevented by wearing frozen gloves starting 15 minutes before DOCEtaxel infusion until 15 minutes after end of DOCEtaxel infusion; gloves should be changed after 45 minutes of wearing to ensure they remain cold during the entire DOCEtaxel infusion.

**TREATMENT:**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose</th>
<th>BCCA Administration Guideline</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOCEtaxel</td>
<td>75 mg/m²²</td>
<td>IV in NS or D5W 250 mL* over 1 hour (use non-DEHP equipment)</td>
</tr>
</tbody>
</table>

* If 75 to 185 mg, use 250 mL bag. If greater than 185 mg, use 500 mL bag.

- Repeat every 21 days x 6 cycles
- Discontinue if no clinical benefit after 2 cycles

**DOSE MODIFICATIONS:**

1. **Hematology**

<table>
<thead>
<tr>
<th>ANC (x 10⁹/L)</th>
<th>Platelets (x 10⁹/L)</th>
<th>Dose*</th>
</tr>
</thead>
<tbody>
<tr>
<td>greater than or equal to 1.5 and greater than 100</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>1 to 1.49 or 75 to 100</td>
<td>75%</td>
<td></td>
</tr>
<tr>
<td>less than 1 or less than 75</td>
<td>Delay</td>
<td></td>
</tr>
</tbody>
</table>

*Consider decreasing DOCEtaxel to 75% if an episode of febrile neutropenia occurs with the prior cycle of treatment
2. **Hepatic dysfunction:**

<table>
<thead>
<tr>
<th>Alkaline phosphatase</th>
<th>AST and/or ALT</th>
<th>Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 2.5 x ULN</td>
<td>and less than 1.5 x ULN</td>
<td>100%</td>
</tr>
<tr>
<td>2.5 to 5 x ULN</td>
<td>1.5 to 5 x ULN</td>
<td>75%</td>
</tr>
<tr>
<td>greater than 5 x ULN</td>
<td>or greater than 5 x ULN</td>
<td>Delay*</td>
</tr>
</tbody>
</table>

*Discuss with contact physician

ULN = upper limit of normal

**PRECAUTIONS:**

1. **Fluid retention:** Dexamethasone premedication must be given to reduce incidence and severity of fluid retention.

2. **Hypersensitivity** reactions to DOCEtaxel are common but it is not necessary to routinely initiate the infusion slowly. If slow initiation of infusion is needed, start infusion at 30 mL/h x 5 minutes, then 60 mL/h x 5 minutes, then 120 mL/h x 5 minutes, then complete infusion at 250 mL/h (for 500 mL bag, continue 250 mL/h for 5 minutes and then complete infusion at 500 mL/h). Refer to BCCA Hypersensitivity Guidelines.

3. **Extravasation:** DOCEtaxel causes pain and tissue necrosis if extravasated. Refer to BCCA Extravasation Guidelines.

4. **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

5. **Hepatic Dysfunction:** DOCEtaxel undergoes hepatic metabolism. Hepatic dysfunction (particularly elevated AST) may lead to increased toxicity and usually requires a dose reduction. Baseline liver enzymes are recommended before cycle 1 and then if clinically indicated (eg, repeat liver enzymes prior to each treatment if liver enzymes are elevated, liver metastases are present or there is severe toxicity such as neutropenia). If liver enzymes are normal and there is no evidence of liver metastases or severe toxicity, check liver enzymes after 3 cycles (ie, at cycle 4). Note: this information is intended to provide guidance but physicians must use their clinical judgment when making decisions regarding monitoring and dose adjustments.

**Call Dr. Cheryl Ho or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.**

Date activated: 1 Jul 2010

Date revised: 1 Aug 2014 (non-PVC changed to non-DEHP)

**REFERENCES:**


